0001569047-23-000003.txt : 20230710 0001569047-23-000003.hdr.sgml : 20230710 20230707173402 ACCESSION NUMBER: 0001569047-23-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230710 DATE AS OF CHANGE: 20230707 EFFECTIVENESS DATE: 20230710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HDL THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001569047 IRS NUMBER: 273015978 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-486274 FILM NUMBER: 231077757 BUSINESS ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 BUSINESS PHONE: 772-453-2770 MAIL ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 D 1 primary_doc.xml X0708 D LIVE 0001569047 HDL THERAPEUTICS, INC. 601 21ST STREET SUITE 300 VERO BEACH FL FLORIDA 32960 772-453-2770 DELAWARE None None Corporation true Michael Matin c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Bryan Brewer c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Dane Andreeff c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Director Gregg Sessa c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Director Biotechnology Decline to Disclose 06b false 2023-06-22 false true true Series X Preferred Shares false 0 7000000 1270074 5729926 false 15 0 0 277000 true false HDL THERAPEUTICS, INC. /s/ Michael Matin Michael Matin Chief Executive Officer 2023-07-07